|
153. Willmann JK, Lutz AM, Paulmurugan R, et al.. Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo. Radiology 2008;248(3):936–944. 154. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50(suppl 1):122S–150S 155. Langenhoff BS, Oyen WJG, Jager GJ, et al.. Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study. J Clin Oncol 2002;20(22):4453–4458.
156. van Waarde A, Jager PL, Ishiwata K, Dierckx RA, Elsinga PH. Comparison of sigma-ligands and metabolic PET tracers for differentiating tumor from inflammation. J Nucl Med 2006;47(1):150–154.
157. Brouwers A, Mulders P, Oosterwijk E, et al.. Pharmacokinetics and tumor targeting of 131I-labeled F(ab’)2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies. Cancer Biother Radiopharm 2004;19(4):466–477. CrossRef, Medline
基于功能分子影像技术对肿瘤治疗疗效评价 |